e-learning
resources
Virtual 2020
Pre-Congress Content
Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Are serum immunoglobulins a predictive biomarker of response for anti-IL5 therapies?
S. LAURET (Toulouse, France), L. Guilleminault (Toulouse, France), E. Noel-Savina (Toulouse, France), G. Prevot (Toulouse, France), D. Brouquieres (Toulouse, France), A. Didier (Toulouse, France)
Source:
Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Session:
Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Session type:
E-poster session
Number:
2266
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. LAURET (Toulouse, France), L. Guilleminault (Toulouse, France), E. Noel-Savina (Toulouse, France), G. Prevot (Toulouse, France), D. Brouquieres (Toulouse, France), A. Didier (Toulouse, France). Are serum immunoglobulins a predictive biomarker of response for anti-IL5 therapies?. 2266
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
The serum YKL-40 is a useful biomarker for asthma
Source: International Congress 2017 – Techniques to treat asthma
Year: 2017
Is there any clinical application for determining the serum cytokines profile in sarcoid patients?
Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis
Year: 2008
Can YKL-40 be used as a biomarker and therapeutic target for adult asthma?
Source: Eur Respir J, 51 (1) 1702194; 10.1183/13993003.02194-2017
Year: 2018
Circulating total leptin as a diagnostic and prognostic biomarker in sepsis
Source: International Congress 2019 – ECMO, ECCO2R and other rescue therapies in acute respiratory failure
Year: 2019
The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis?
Source: International Congress 2017 – Rare diseases
Year: 2017
Serum cytokine and antiviral antibody in the clinical course of sarcoidosis
Source: Eur Respir J 2003; 22: Suppl. 45, 46s
Year: 2003
Relationship between pre-treatment specific IgE and the response to omalizumab therapy
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
Serum KL-6 as a biomarker to assess risk of worse outcome in patients with SARS-CoV2 infection
Source: Virtual Congress 2021 – COVID - 19 biomarkers
Year: 2021
Free serum IgE suppression with omalizumab and clinical outcomes in asthma
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019
Immunoproteasome function as a potential biomarker for asthma severity and response to therapy
Source: Virtual Congress 2021 – Emerging new mechanisms of chronic lung disease
Year: 2021
Free plasmatic circulating DNA as prognostic and diagnostic lung cancer biomarker
Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases
Year: 2008
Clinical significance of serum MRGPRX2 as a new biomarker in allergic asthma
Source: International Congress 2019 – Research and innovation in airway diseases
Year: 2019
Serum eosinophil cationic protein as a potential biomarker for interleukin-5 antibody treatment in patients with severe uncontrolled eosinophilic asthma
Source: International Congress 2018 – Biomarkers for evaluating asthma
Year: 2018
Predictive biomarker of immune checkpoint inhibitors efficacy
Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine
Year: 2019
Altered Fc galactosylation in IgG
4
is a potential serum marker for chronic lung disease
Source: ERJ Open Res, 4 (3) 00033-2018; 10.1183/23120541.00033-2018
Year: 2018
Change in serum surfactant protein (SP)-A, SP-D and KL-6 predict the therapeutic effect of antifibrotic drugs in IPF.
Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia
Year: 2019
KL-6 is a useful serum biomarker for early detection of interstitial lung disease
Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities
Year: 2012
Elevation of circulating endothelial cell levels in lung cancer – a new prognostic and/or predictive marker?
Source: Annual Congress 2008 - Diagnosis and prognosis in thoracic oncology
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept